We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recovery Therapy Trial

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00239122
First Posted: October 14, 2005
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
William Buckland Foundation
Information provided by:
Melbourne Health
  Purpose
This project will systematically apply a specialist version of Cognitive Behaviour Therapy (CBT), known as Recovery Therapy, to a random sample of patients with psychotic disorders. Previously, the therapy has been developed and efficacy established, but the extent of applicability to (unselected) mental health service patients is unknown. The main aim is to establish the extent to which this therapy is acceptable and effective for mental health service clients. A secondary aim is to develop guidelines for the conduct of such therapy in public mental health settings.

Condition Intervention
Schizophrenia Psychotic Disorders Mood Disorders Behavioral: Recovery Therapy (Cognitive Behaviour Therapy for psychosis)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Applicability of CBT to Unselected Mental Health Service Clients With Psychotic Disorders

Resource links provided by NLM:


Further study details as provided by Melbourne Health:

Primary Outcome Measures:
  • To determine the applicability of cognitive behaviour therapy for psychosis in the "real world" setting of ordinary mental health services

Secondary Outcome Measures:
  • To establish rates of uptake of Recovery Therapy amongst clients at a community mental health service
  • To establish effectiveness of therapy in clients who received a defined length of therapeutic contact (12-24 sessions)
  • To identify factors predicting uptake and effectiveness

Estimated Enrollment: 94
Study Start Date: June 2000
Estimated Study Completion Date: February 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • acceptance by the participating Community Mental Health Services for case management
  • a preliminary DSM-IV diagnosis of schizophrenia, schizoaffective disorder, mood disorder with psychotic features, or delusional disorder
  • a recovery "need" in one of the areas addressed by the therapy

Exclusion Criteria:

  • a preliminary DSM-IV diagnosis of brief psychotic disorder, drug-induced psychosis, mood disorder without hallucinations or delusions, or any other disorder (eg. personality disorder, PTSD) even where psychotic features are/have been present
  • non-English speaking
  • comorbid intellectual disability
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00239122


Locations
Australia, Victoria
Whittlesea Community Mental Health Service
Epping, Victoria, Australia, 3076
Darebin Community Mental Health Service
Preston, Victoria, Australia, 3072
Sponsors and Collaborators
Melbourne Health
William Buckland Foundation
Investigators
Principal Investigator: John Farhall, BA(Hons), MA LaTrobe University, NorthWestern Mental Health
  More Information

ClinicalTrials.gov Identifier: NCT00239122     History of Changes
Other Study ID Numbers: E00013
First Submitted: October 12, 2005
First Posted: October 14, 2005
Last Update Posted: December 9, 2005
Last Verified: October 2005

Keywords provided by Melbourne Health:
Cognitive Therapy
Psychotic Disorders
Treatment Outcome

Additional relevant MeSH terms:
Disease
Schizophrenia
Mental Disorders
Psychotic Disorders
Mood Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders